Morgan Stanley Maintains Overweight on Avalyn Pharma, Lowers Price Target to $53
Benzinga Newsdesk 14 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and lowers the price target from $57 to $53.
Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and lowers the price target from $57 to $53.
